Anti-N-methyl-d-aspartate receptor encephalitis in Māori and Pacific Island children in New Zealand

Developmental Medicine and Child Neurology

Volumn 59, Issue 7, 2017, Pages 719-724

  Jones, Hannah F ^a   Mohammad, Shekeeb S ^b   Reed, Peter W ^a   Dunn, Paul P J ^c   Steele, Richard H ^d   Dale, Russell C ^b   Sharpe, Cynthia ^a  

^a STARSHIP CHILDREN S HOSPITAL   (New Zealand)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c LEICESTER GENERAL HOSPITAL   (United Kingdom)

^d VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; METHOTREXATE; RITUXIMAB; STEROID;

ADOLESCENT; ADULT; ANTI N METHYL D ASPARTATE RECEPTOR ENCEPHALITIS; ARTICLE; CASE STUDY; CEREBROSPINAL FLUID ANALYSIS; CHILD; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; IMMUNOTHERAPY; INCIDENCE; MALE; MAORI (PEOPLE); NEW ZEALAND; OUTCOME ASSESSMENT; PACIFIC ISLANDS; PLASMAPHERESIS; PRIORITY JOURNAL; RANKIN SCALE; RETROSPECTIVE STUDY; AFTERCARE; ANTI-N-METHYL-D-ASPARTATE RECEPTOR ENCEPHALITIS; EPIDEMIOLOGY; ETHNOLOGY; GENETIC PREDISPOSITION; INFANT; OCEANIC ANCESTRY GROUP; PRESCHOOL CHILD; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADOLESCENT; AFTERCARE; ANTI-N-METHYL-D-ASPARTATE RECEPTOR ENCEPHALITIS; CHILD; CHILD, PRESCHOOL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; INFANT; MALE; NEW ZEALAND; OCEANIC ANCESTRY GROUP; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85016296901     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/dmcn.13420     Document Type: Article

References (20)

1. Wright S, Hacohen Y, Jacobson L, et al. N-methyl-D-aspartate receptor antibody-mediated neurological disease: results of a UK-based surveillance study in children. Arch Dis Child 2015; 100: 521–6.
2. Gable MS, Gavali S, Radner A, et al. Anti-NMDA receptor encephalitis: report of ten cases and comparison with viral encephalitis. Eur J Clin Microbiol Infect Dis 2009; 28: 1421–9.
3. Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010; 133: 1655–67.
4. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013; 12: 157–65.
5. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011; 10: 63–74.
6. Florance NR, Davis RL, Lam C, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009; 66: 11–18.
7. Masghati S, Nosratian M, Dorigo O. Anti-N-methyl-aspartate receptor encephalitis in identical twins. Obstet Gynecol 2014; 123: 433–5.
8. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7: 1091–8.
9. Florance-Ryan N, Dalmau J. Update on anti-N-methyl-D-aspartate receptor encephalitis in children and adolescents. Curr Opin Pediatr 2010; 22: 739–44.
10. Mohammad SS, Jones H, Hong M, et al. Symptomatic treatment of children with anti-NMDAR encephalitis. Dev Med Child Neurol 2015; 58: 376–84.
11. Department of Public Health. (2013) Socioeconomic Deprivation Indexes: NZDep and NZiDep 2013. Available at: http://www.otago.ac.nz/wellington/departments/publichealth/research/hirp/otago020194.html (accessed 17 November 2015).
12. Armangue T, Titulaer MJ, Málaga I, et al. Pediatric anti-N-methyl-D-aspartate receptor encephalitis – clinical analysis and novel findings in a series of 20 patients. J Pediatr 2013; 162: 850–56.e2.
13. Sartori S, Nosadini M, Cesaroni E, et al. Paediatric anti-N-methyl-D-aspartate receptor encephalitis: the first Italian multicenter case series. Eur J Paediatr Neurol 2015; 19: 453–63.
14. Zekeridou A, Karatoni E, Viaccoz A, et al. Treatment and outcome of children and adolescents with N-methyl-D-aspartate receptor encephalitis. J Neurol 2015; 262: 1859–66.
15. Nosadini M, Mohammad SS, Ramanathan S, Brilot F, Dale RC. Immune therapy in autoimmune encephalitis: a systematic review. Expert Rev Neurother 2015; 15: 1391–419.
16. Byrne S, Walsh C, Hacohen Y, et al. Earlier treatment of NMDAR encephalitis in children results in better outcome. Neurol Neuroimmunol Neuroinflamm 2015; 2: e130.
17. Dale RC, Irani SR, Brilot F, et al. N-methyl-D-aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica. Ann Neurol 2009; 66: 704–9.
18. Edinur H, Dunn PPJ, Hammond L, et al. HLA and MICA polymorphism in Polynesians and New Zealand Māori: implications for ancestry and health. Hum Immunol 2013; 74: 1119–29.
19. Concannon A, Rudge S, Yan J, Reed P. The incidence, diagnostic clinical manifestations and severity of juvenile systemic lupus erythematosus in New Zealand Māori and Pacific Island children: the Starship experience (2000–2010). Lupus 2013; 22: 1156–61.
20. Watrin L, Chawche F, Larre P, Neau J, Mathis S, Fournier E. Guillain-Barré syndrome (42 cases) occurring during a zika virus outbreak in French Polynesia. Medicine 2016; 95: e3257.